Source link : https://newshealth.biz/health-news/orforglipron-phase-3-success-prompts-submissions-for-obesity/
Lilly’s investigational drug met primary and key secondary endpoints in ATTAIN-2, showing significant weight loss and reduced A1c in people with obesity or overweight and type 2 diabetes. Medscape Medical News Source link : https://www.medscape.com/viewarticle/orforglipron-phase-3-success-prompts-submissions-obesity-2025a1000mkb?src=rss Author : Publish date : 2025-08-26 19:34:00 Copyright for syndicated content belongs to the linked Source.
The post Orforglipron Phase-3 Success Prompts Submissions for Obesity first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-26 19:34:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8